Navigation Links
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Date:2/6/2009

can have a significant impact on patient lives. Nplate represents a potentially high value option for these patients."

The EU approval of Nplate is based on data from two separate placebo-controlled Phase 3 studies, demonstrating that platelet counts were raised and sustained in 83 percent of patients for both splenectomised and non-splenectomised groups when treated with Nplate. Additionally, patients treated with Nplate were able to reduce or discontinue concomitant medications such as corticosteroids which are often not well tolerated. Nplate patients also used far less "emergency" medications such as IVIG and Win-Rho, whose effects are transient.

Upon completion of the Phase 3 studies almost 90 percent of patients elected to subsequently enroll into the Nplate long term extension study which demonstrated that Nplate continued to effectively increase and sustain platelet counts. In this open label long term extension study the average treatment period was 76 weeks and the longest duration of treatment was 204 weeks.

Key findings from the extension study showed platelet counts of Nplate-treated patients were increased from baseline by 20,000 platelets per microliter more than 80 percent of the time in 47 percent of patients and more than half the time in 67 percent of patients.

"Amgen is committed to advancing the discovery and development of new therapies for grievous illnesses where there is an unmet need," said Willard Dere, M.D., senior vice president and international chief medical officer at Amgen. "The European approval of Nplate is the result of more than 15 years of research and represents an important biotechnology milestone as it is the first approved peptibody, an innovative platform for delivering targeted therapies."

About Adult ITP

In patients with ITP, platelets - or blood elements needed to prevent bleeding - are destroyed by the patient's
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
2. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
3. Norditropin(R) Approved for Treatment of Children with Short Stature Associated with Turner Syndrome
4. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
5. Newly Approved HIV Drug Shows Great Promise
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Approved by FDA for Acute Treatment of Migraine
8. Divigel(R) (estradiol gel) 0.1 Percent Offers Lowest Approved Dose of Estradiol for Treatment of Moderate to Severe Hot Flashes Associated with Menopause
9. FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... LAWRENCE, Mass. , Dec. 22, 2014 /PRNewswire/ ... a leading manufacturer of innovative dialysis products, announced ... (FDA) has cleared its System One™ to perform ... sleeping, known as home nocturnal hemodialysis. NxStage,s® System ... cleared by the FDA for this indication. ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... , Dec, 22, 2014  Eiger BioPharmaceuticals ... 2a study of lonafarnib in patients with chronic ... conducted at the National Institutes of Health (NIH) ... .  The double-blinded, randomized, placebo-controlled, dose ascending study ... daily and 200 mg twice daily for 28 ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... , a leading provider of therapeutic drug monitoring and ... today the appointment of David Cohen to Chief Operating ... responsible for new business analysis and development to expand ... Millennium,s legislative initiatives and community outreach programs. ...
... Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast:What: ... presented at ESCWhen: , Wednesday, September 1, 2010 at 4:00 ... Live on the Internet.  Simply log onto our Web site listed ... a replay of the webcast will be available for a limited ...
Cached Medicine Technology:Millennium Laboratories Announces New Chief Operating Officer David Cohen 2
(Date:12/24/2014)... As 2014 draws to a close, ... investing time and money into a new or tankless ... specializes in tankless and eco-friendly products or service. Greenstar ... heater in 2015 to research “green” and environmentally friendly ... Home Services specializes in eco-friendly and environmentally conscious ...
(Date:12/24/2014)... York (PRWEB) December 24, 2014 In ... the United States rode bicycles, hand cycles and recumbent ... D.C. in the inaugural CanAm Veterans’ Challenge . ... non-profit World T.E.A.M. Sports about this inspiring ride, is ... more than 50 full color photographs taken during the ...
(Date:12/24/2014)... 23, 2014 (HealthDay News) -- Each year, more than ... the United States occur because of extreme heat conditions, ... study finds that heat stroke is the leading cause ... as kidney failure and urinary tract infections, also put ... soar. The new data should help health care ...
(Date:12/24/2014)... -- Though most patients with obsessive-compulsive disorder (OCD) can ... percent to 20 percent have a form of the ... However, patients with this so-called "refractory OCD" do ... brain surgery that disables certain brain networks believed to ... patients most likely to benefit from the surgery, known ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 B. E. ... to healthcare providers, has been retained to lead a ... Tri-City Medical Center in Oceanside, Calif. The top ... B. E. Smith has recently placed more than 900 ... is a community owned, 397-bed, Gold Seal-approved, full-service acute-care ...
Breaking Medicine News(10 mins):Health News:Greenstar Home Services Offers Tankless Water Heater Advice to Local Homeowners 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 2Health News:New Commemorative Book Celebrates CanAm Veterans’ Challenge Bike Ride 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3
... Executive ... Chairman, SOUTH SAN ... company focused on the discovery,and development of drugs for major medical needs ... will step down today as President and Chief Executive Officer to,pursue another ...
... SAN DIEGO, Oct. 1 Amylin Pharmaceuticals,Inc. ... the U.S. Food and Drug,Administration (FDA) has ... pen-injector devices for administering SYMLIN(R),(pramlintide acetate) injection. ... dosing to improve mealtime glucose control. ...
... Presented at ERS 17th Annual Congress -, ... Inc.,today announced the submission of a pre-market approval ... (FDA) requesting regulatory,approval to market the Emphasys endobronchial ... Zephyr EBV is a minimally invasive and potentially,reversible ...
... have been homeless for any period of time after ... problems accessing health care than those with stable housing ... of Archives of Pediatrics & Adolescent Medicine, one of ... any period of time after leaving the foster care ...
... 1 Highlands Behavioral,Health System, a UHS facility, ... of Excellence for teens in crisis. The new ... Highlands Behavioral,Health ( http://www.highlandsbhs.com ) in Littleton, Colo. ... said the,Adolescent Center of Excellence represents an expansion ...
... was recently announced,as a silver winner in ... by,ComPsych Corporation. Concentra was selected based on ... achieved results. Concentra, a leader in ... commitment to better health and wellness among ...
Cached Medicine News:Health News:Renovis Announces Management Changes 2Health News:Renovis Announces Management Changes 3Health News:Renovis Announces Management Changes 4Health News:Renovis Announces Management Changes 5Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 2Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 3Health News:FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use 4Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 2Health News:Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy 3Health News:Poor health care access common among youth leaving foster system 2Health News:Poor health care access common among youth leaving foster system 3Health News:New Denver Area Program Developed For Teens in Crisis 2Health News:Concentra Honored With Silver Health at Work(SM) Award by ComPsych(R) Corp. 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: